CYP4

CYP4 (cytochrome P450 family 4) enzymes are microsomal monooxygenases that primarily catalyze the ω-oxidation of endogenous fatty acids and eicosanoids, thereby regulating the metabolic turnover of bioactive lipid mediators involved in cellular signaling pathways^[1][2]. Through the metabolism of arachidonic acid, leukotriene B₄, and prostaglandins, CYP4 enzymes participate in eicosanoid-dependent processes that influence inflammation, cardiovascular homeostasis, and lipid-associated physiological responses^[1][3]. Mechanistically, CYP4-mediated fatty acid hydroxylation contributes to the generation or inactivation of signaling molecules, linking lipid metabolism with disease-associated pathways in cancer, cardiovascular disorders, inflammatory conditions, and genetic diseases^[1][2]. Compared with xenobiotic-metabolizing CYP1, CYP2, and CYP3 family members, human CYP4 subfamilies are more closely associated with endogenous substrate metabolism and include CYP4A, CYP4B, CYP4F, CYP4V, CYP4X, and CYP4Z isoforms that exhibit distinct substrate preferences and tissue expression patterns^[1]. Several CYP4 enzymes show aberrant expression in tumor tissues, and elevated expression of specific CYP4A, CYP4F, CYP4B1, or CYP4Z1 isoforms has been associated with tumor progression and poor clinical outcomes in selected cancer models^[1]. For experimental applications, small-molecule CYP4 inhibitors, including inhibitors of CYP4A11-mediated 20-HETE synthesis, are widely used to investigate CYP4-dependent lipid signaling pathways and evaluate potential therapeutic strategies targeting dysregulated eicosanoid metabolism^[1][3].